Prescient Therapeutics
- Short interest
- <0.01%
- 0.00 pp 30d
- as of 14 Apr 2026
- Reported shorts
- 11K
- Shares on issue
- 1.052B
Prescient Therapeutics (PTX) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASX
Google NewsWhy Is Prescient Therapeutics (ASX:PTX) Stock Up 7% Today? - Kalkine
Why Is Prescient Therapeutics (ASX:PTX) Stock Up 7% Today? Kalkine
What's Behind Prescient Therapeutics (ASX:PTX) Share Price Change Today? Stock Up 10.91% - Kalkine
What's Behind Prescient Therapeutics (ASX:PTX) Share Price Change Today? Stock Up 10.91% Kalkine
What Did Prescient Therapeutics (ASX:PTX) Report in Its September 2026 Quarter for the PTX-100 Lymphoma Study? - Kalkine
What Did Prescient Therapeutics (ASX:PTX) Report in Its September 2026 Quarter for the PTX-100 Lymphoma Study? Kalkine
Chair Address and CEO AGM Presentation
other announcement
September 2026 Quarterly Update and Appendix 4C
other announcement
Change of Director's Interest Notice
director_dealing announcement
Change of Director's Interest Notice
director_dealing announcement
Change of Director's Interest Notice
director_dealing announcement
Notification regarding unquoted securities - PTX
other announcement
Application for quotation of securities - PTX
other announcement
Application for quotation of securities - PTX
other announcement
Proposed issue of securities - PTX
other announcement
PTX Successfully Completes $6m Raise Via SPP and Placement
capital_raise announcement
StockheadPrescient raise targets $8 million to advance cancer drug candidate
PTX-100 is advancing through a Phase 2a clinical trial in cutaneous T-cell lymphoma (CTCL), a rare form of blood cancer ... Read More The post Prescient raise targets $8 million to advance cancer drug candidate appeared first on Stockhead.
Small CapsPrescient Therapeutics Hits Enrolment Threshold for PTX-100 Phase 2a Trial Review
Prescient Therapeutics hits enrolment milestone: PTX-100 Phase 2a reaches 20 evaluable patients; first Dose Optimisation Committee review in December 2026.
Who’s Who with Prescient Therapeutics : PTX100 First in class
Tylah Tully looks at Prescient Therapeutics, whose targeted treatments are designed to stop cancer cells from growing and surviving. ... Read More The post Who’s Who with Prescient Therapeutics : PTX100 First in class appeared first on Stockhead.
Prescient Therapeutics Advances Lead Asset PTX-100 through Phase 2a Trials as Pharmaceutical Dealmaking Accelerates
Prescient advances PTX-100 in Phase 2a for CTCL; DOC review set for Dec 2026 as Prescient accelerates toward registration data amid booming pharma dealmaking.
Long Shortz with Prescient Therapeutics: PTX100 hits key dose optimisation milestone
The dose optimisation committee could influence the next stage of development of PTX-100 as the company reaches halfway dosing milestone. ... Read More The post Long Shortz with Prescient Therapeutics: PTX100 hits key dose optimisation milestone appeared first on Stockhead.
Update - Proposed issue of securities - PTX
other announcement
Prescient Therapeutics - Extension of Share Purchase Plan
capital_raise announcement
Notice of Annual General Meeting/Proxy Form
other announcement
Update - Proposed issue of securities - PTX
other announcement
Prescient Therapeutics - Extension of Share Purchase Plan
capital_raise announcement
Prescient advances first-in-class cancer drug as big pharma shops for deals
PTX-100 is now in a Phase 2a trial for cutaneous T-cell lymphoma, a rare form of blood cancer with limited ... Read More The post Prescient advances first-in-class cancer drug as big pharma shops for deals appeared first on Stockhead.
Prescient lymphoma drug trial hits key review milestone
Prescient has reached the enrolment threshold that will trigger the first dose optimisation review of its Phase 2a PTX-100 trial ... Read More The post Prescient lymphoma drug trial hits key review milestone appeared first on Stockhead.
PTX-100 CTCL Phase 2a study reaches review milestone
other announcement
KalkineWhat’s Next for Prescient Therapeutics (ASX:PTX) After Capital Raise?
Highlights Prescient Therapeutics has opened a capital raising initiative to help fund its lead cancer therapy program. Proceeds are earmarked for advancing an ongoing clinical study targeting hard-to-treat blood and solid tumour cancers. Regulatory designations secured in overseas markets continue to underpin the clinical-stage biotechnology company's development pathway. Prescient Therapeutics Ltd, the Melbourne-based clinical-stage biotechnology company developing a novel cancer therapy ca...
Prescient Therapeutics targets cancer with world-first GGTase-1 inhibitor
Prescient is at the forefront of targeted cancer treatment with its lead drug candidate PTX-100, the world’s first GGTase-1 inhibitor ... Read More The post Prescient Therapeutics targets cancer with world-first GGTase-1 inhibitor appeared first on Stockhead.
Prescient Share Purchase Plan Investor Presentation
capital_raise announcement
Prescient Therapeutics Opens SPP to Raise $7m Today
other announcement
Prescient Therapeutics Launches Share Purchase Plan for $7m
capital_raise announcement
Prescient Therapeutics (ASX:PTX) trial hits 28 patients as cash runway tightens into 2027 - Stocks Down Under
Prescient Therapeutics (ASX:PTX) trial hits 28 patients as cash runway tightens into 2027 Stocks Down Under
Why Prescient Therapeutics (ASX:PTX) Tops Biotech Penny Watchlists
Highlights Prescient Therapeutics is advancing personalised cancer treatments, with its OmniCAR platform designed to give clinicians greater control over CAR-T style therapies. Trial milestones and cash runway remain the dominant forces shaping sentiment toward clinical-stage oncology juniors on the ASX. Immutep's late-stage lung cancer combination study has passed the halfway mark of enrolment, while PolyNovo anchors the device end of healthcare watchlists. What keep...
Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation - simplywall.st
Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation simplywall.st
Top Smallcap Stocks to Watch: Prescient Therapeutics (ASX:PTX) Leads the Proof Test
Highlights ASX Smallcap Stocks are attracting closer scrutiny as markets favour evidence, resilience and disciplined execution over broad thematic excitement. Prescient Therapeutics (ASX:PTX) and ECS Botanics (ASX:ECS) illustrate how healthcare and cannabis-focused small caps are being assessed through quality, funding strength and operational progress. Sector rotation, global uncertainty and changing market leadership are encouraging closer att...
ASX Preview: Can Prescient Therapeutics (ASX:PTX) and Renascor Resources (ASX:RNU) Lead Penny Stocks Today?
Highlights Australian shares are expected to begin the session with penny stocks attracting renewed attention as investors become increasingly selective about speculative opportunities. Companies demonstrating stronger cash discipline, funding certainty and credible operational progress are emerging as market favourites. Prescient Therapeutics Ltd (ASX:PTX), Renascor Resources Ltd (ASX:RNU), ECS Botanics Holdings Ltd (ASX:ECS) and Sayona Mining Ltd (ASX:SYA) are expec...
PTX Dr Rosalind Wilson appointed as Chief Medical Officer
other announcement
PTX Trial Momentum Builds as Oncology Pipeline Expands
Highlights PTX-100 clinical program advances with broader global reach Patient enrolment strengthens across key regions Cell therapy platforms continue strategic progress Prescient Therapeutics is advancing its oncology pipeline with steady clinical progress, expanding global trial presence, and continued development across innovative cell therapy platforms. Expanding Clinical Footprint Drives Momentum Prescient Therapeutics Ltd (ASX:PTX) continues to strengthen its position within the ...
PTX secures EU Authorisation to commence PTX-100 Trial
other announcement